ArticleNeoplasia (New York, N.Y.)2025

Phase I clinical trial of a novel procaspase-3 activator SM-1 with temozolomide in recurrent high-grade gliomas.

Mengqian Huang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.